Multiple Myeloma

>

Latest News

In the analysis comparing D-VRd with other regimens for MRD-negative CR rate, there was an 81% probability that it was favorable vs Isa-VRd.
Which Therapy Has the Best Efficacy in Transplant-Ineligible NDMM?

October 1st 2025

D-VRd had a 72% chance of providing superior PFS outcomes vs isatuximab plus VRd in patients with transplant-ineligible NDMM.

Treatment with anito-cel shows a predictable and manageable safety profile among those with relapsed/refractory multiple myeloma in the iMMagine-1 trial.
Anito-cel Yields Enduring Efficacy in Relapsed/Refractory Multiple Myeloma

September 30th 2025

The Lived Experience of Talquetamab Therapy in a Patient With Multiple Myeloma
The Lived Experience of Talquetamab Therapy in a Patient With Multiple Myeloma

September 27th 2025

The median PFS was not reached with daratumumab-lenalidomide maintenance after a median follow-up of 49 months in those with multiple myeloma.
Dara-KRd Regimen Displays Prolonged PFS in Newly Diagnosed Multiple Myeloma

September 22nd 2025

CEPHEUS Highlights Efficacious, Safe Regimen for Transplant-Ineligible/Deferred Multiple Myeloma
CEPHEUS Highlights Efficacious, Safe Regimen for Transplant-Ineligible/Deferred Multiple Myeloma

September 21st 2025

Video Series
Video Interviews
Podcasts
A panel of clinical pharmacists discussed strategies for mitigating toxicities across different multiple myeloma, lymphoma, and leukemia populations.
Samantha Shenoy, NP, MSN, discusses how her role plays a vital part in patient care for those receiving talquetamab for multiple myeloma.
James R. Berenson, MD, describes ongoing efforts to evaluate treatment with JAK inhibitors like ruxolitinib among patients with multiple myeloma.
Registered nurses discuss research related to agents like ciltacabtagene autoleucel presented at the 2024 Oncology Nursing Society Congress.
Experts discuss key data updates in real-world newly diagnosed multiple myeloma practices, and how these findings may change the treatment paradigm.
Experts from Mayo Clinic and The University of Texas MD Anderson Cancer Center discuss results from multiple myeloma trials presented at the 2023 American Society of Clinical Oncology Annual Meeting and how they may apply to clinical practice.
Krina Patel, MD, MSc, discusses research and initiatives that may help to mitigate disparities in patients with multiple myeloma including factors such as gender, race, and ethnicity.
Paul G. Richardson, MD, and Christina Gasparetto, MD, offer insights into the use of proteasome inhibitors in relapsed or refractory multiple myeloma.
Latest CME Events & Activities

More News